Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 34904799

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Jan 27
First author
Tilly H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013.
    note
    Source null
    related pmid
    35167823
    relationship
    Comment in
  2. citation
    N Engl J Med. 2023 Aug 24;389(8):764-766. doi: 10.1056/NEJMc2306105.
    note
    Source null
    related pmid
    37611128
    relationship
    Comment in

Authors and identifiers

  1. name
    Tilly H
    type
    Author
  2. name
    Morschhauser F
    type
    Author
  3. name
    Sehn LH
    type
    Author
  4. name
    Friedberg JW
    type
    Author
  5. name
    Trněný M
    type
    Author
  6. name
    Sharman JP
    type
    Author
  7. name
    Herbaux C
    type
    Author
  8. name
    Burke JM
    type
    Author
  9. name
    Matasar M
    type
    Author
  10. name
    Rai S
    type
    Author
  11. name
    Izutsu K
    type
    Author
  12. name
    Mehta-Shah N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tilly H
    type
    Author
  2. name
    Morschhauser F
    type
    Author
  3. name
    Sehn LH
    type
    Author
  4. name
    Friedberg JW
    type
    Author
  5. name
    Trněný M
    type
    Author
  6. name
    Sharman JP
    type
    Author
  7. name
    Herbaux C
    type
    Author
  8. name
    Burke JM
    type
    Author
  9. name
    Matasar M
    type
    Author
  10. name
    Rai S
    type
    Author
  11. name
    Izutsu K
    type
    Author
  12. name
    Mehta-Shah N
    type
    Author
bibliography ids
  1. nci-bib-40f2298c7ab6ab4a1bf51f6a
book metadata
content sha256
e34ab597f099bbb80d9704e0b154bc9cd942fe6509a64a7688fbff6ad6659ff7
document type
citation
dois
  1. 10.1056/NEJMoa2115304
electronic publication date
display
2021 Dec 14
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34904799
immutable id
pubmed:34904799@e34ab597f099bbb80d9704e0b154bc9cd942fe6509a64a7688fbff6ad6659ff7
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
4
name
The New England journal of medicine
nlm unique id
0255562
pages
351-363
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013.
    note
    Source null
    related pmid
    35167823
    relationship
    Comment in
  2. citation
    N Engl J Med. 2023 Aug 24;389(8):764-766. doi: 10.1056/NEJMc2306105.
    note
    Source null
    related pmid
    37611128
    relationship
    Comment in
outcomes validated
false
pmid
34904799
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
c351dd9f0d0780b8a1b85c5c1e867c68c6ee15f455c27b771400b5bdb752487c
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Jan 27
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34904799/
title
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Preserved source evidence · Independent clinical review pending · Not medical advice